Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jiangsu Recbio Technology Co., Ltd. Proxy Solicitation & Information Statement 2025

May 30, 2025

50426_rns_2025-05-30_76b5e76a-90d6-448f-a255-13a4fea24852.pdf

Proxy Solicitation & Information Statement

Open in viewer

Opens in your device viewer

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

瑞科生物
——RECBIPO

Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

NOTICE OF 2024 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the 2024 Annual General Meeting (the “AGM”) of Jiangsu Recbio Technology Co., Ltd. (the “Company”) will be held at 10:00 a.m. on Friday, June 20, 2025 at Conference Room, 3/F, Building G29, Standard Plant, China Medical City Phase 6, Medical High-tech District, Taizhou City, Jiangsu Province, the People’s Republic of China for the following purposes (special resolution marked with *):

RESOLUTIONS

  1. To consider and approve the Resolution on 2024 Financial Accounts Report of the Company;
  2. To consider and approve the Resolution on 2025 Financial Budget Report of the Company;
  3. To consider and approve the Resolution on 2024 Work Report of the Board of Directors of the Company;
  4. To consider and approve the Resolution on 2024 Annual Report of the Company;
  5. To consider and approve the Resolution on 2024 Work Report of the Supervisory Board of the Company;
  6. To consider and approve the Resolution on Engagement of Auditors of the Company for 2025;
  7. To consider and approve the Resolution on 2025 Remuneration Scheme for Directors and Supervisors of the Company;
  8. To consider and approve the Resolution on 2024 Profit Distribution Plan of the Company;

  1. *To consider and approve the Resolution on Grant of General Mandate to the Board to Issue Additional Shares of the Company;
  2. To consider and approve the Resolution on the Proposed Appointment of the Board Observer;
  3. To consider and approve the Resolution on the Proposed Changes in Business Scope of the Company; and
  4. *To consider and approve the Resolution on the Proposed Amendments to the Articles of Association.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. LIU Yong
Chairman

Jiangsu Province, the PRC
May 30, 2025


  • 3 -

Notes:

  1. All resolutions at the AGM will be taken by poll (except where the chairman decides to allow a resolution relating purely to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The AGM will be held by way of on-site voting. The results of the poll will be published on the websites of the Company at www.recbio.cn and Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk after the AGM.

  2. Any Shareholder entitled to attend and vote at the AGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a Shareholder of the Company.

  3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the Company's headquarters and registered office in the PRC (for holders of Domestic Shares and Unlisted Foreign Shares) or H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares), at least 24 hours before the AGM (i.e. before 10:00 a.m. on Thursday, June 19, 2025) or any adjournment thereof. Completion and return of the form of proxy will not preclude a Shareholder from attending and voting at the AGM or any adjournment thereof should he/she so wish.

  4. For the purpose of determining the list of holders of H Shares who are entitled to attend the AGM, the H Share Register of members of the Company will be closed from Tuesday, June 17, 2025 to Friday, June 20, 2025, both days inclusive, during which period no transfer of H shares will be registered. In order to be eligible to attend and vote at the AGM, unregistered holders of the H Shares shall ensure all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Monday, June 16, 2025 for registration.

  5. In case of joint Shareholders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.

  6. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.

  7. A Shareholder or his/her proxy should provide proof of identity when attending the AGM.

  8. Further details of the resolutions will be included in the circular of the Company dated May 30, 2025.

  9. References to dates and times in this notice are to Hong Kong dates and times.

As at the date of this notice, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive director, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.